[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-465707-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-465707-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","redefining-chemotherapy-related-headaches-from-pathobiology-to-differential-diagnosis-and-management","Redefining Chemotherapy-Related Headaches - From Pathobiology to Differential Diagnosis and Management","","Chemotherapy-related headaches pose a significant challenge to cancer patients’ well-being and treatment adherence, yet the underlying mechanisms and pathobiology remain incompletely understood, limiting reliable therapeutic options. This review synthesizes emerging causes and molecular and functional processes, addressing clinical and research gaps while emphasizing iatrogenic and psychogenic contributions. It stresses the need to distinguish chemotherapy-related headaches from primary headache disorders, and it highlights evolving biomarkers and mechanistic models that may enable differential diagnosis and more effective interventions. Improved recognition is expected to strengthen adherence and post-treatment quality of life as cancer survival improves.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/redefining-chemotherapy-related-headaches-from-pathobiology-to-differential-diagnosis-and-management/465707/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/redefining-chemotherapy-related-headaches-from-pathobiology-to-differential-diagnosis-and-management/465707.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why are chemotherapy-related headaches a major problem for cancer patients?","Question",{"text":62,"@type":63},"They significantly affect well-being and treatment adherence, contributing to reduced compliance and deterioration of patient quality of life.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What does the review claim about the pathobiology of chemotherapy-related headaches?",{"text":67,"@type":63},"Although such headaches are prevalent, the mechanisms and pathobiology are described as elusive, and mechanistic and translational studies remain scarce.",{"name":69,"@type":60,"acceptedAnswer":70},"How should chemotherapy-related headaches be differentiated from other headache disorders?",{"text":71,"@type":63},"The review highlights the need to distinguish chemotherapy-related headaches from primary headache disorders in cancer patients, including migraines and tension-type headaches.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},465707,1792175642,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nRedefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management  \nChioma V. Nnadi 1, David B. Olawade 2,3,4,5, Susan Shorter 1, Emmanuel O. Oisakede 6,7, Stergios Boussios 8,9,10,11,12,13,14 and Saak V. Ovsepian 1,15, *  \nAcademic Editor: ErikA.C. Wiemer  \nReceived: 31 October 2025  \nRevised: 22 December 2025  \nAccepted: 23 December 2025  \nPublished: 26 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Faculty of Engineering and Science, University of Greenwich, London ME4 4TB, UK  \n2 Department of Allied and Public Health, School of Health, Sport and Bioscience, University of East London, London E16 2RD, UK; [d.olawade@uel.ac.uk](d.olawade@uel.ac.uk)  \n3 Department of Research and Innovation, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK  \n4 Department of Business, Management and Health, York St John University, London E14 2BA, UK  \n5 School of Health and Care Management, Arden University, Arden House, Middlemarch Park, Coventry CV3 4FJ, UK  \n6 Department of Clinical Oncology, Leeds Teaching Hospitals Trust, Leeds LS9 7TF, UK  \n7 Department of Health Research, University of Leeds, Leeds LS2 9JT, UK  \n8 Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK; [stergios.boussios@nhs.net](stergios.boussios@nhs.net)  \n9 Faculty of Medicine, Health, and Social Care, Canterbury Christ Church University, Canterbury CT2 7PB, UK  \n10 Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King’s College London, Strand, London WC2R 2LS, UK  \n11 Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, UK  \n12 AELIA Organisation, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece  \n13 Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece  \n14 Department of Medical Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece  \n15 Faculty of Medicine, Tbilisi State University, Tbilisi 0179, Georgia  \n* Correspondence: [saak.ovsepian@gmail.com](saak.ovsepian@gmail.com)  \nAbstract  \nChemotherapy-related headaches pose a significant challenge to the well-being and treatment adherence of cancer patients. Despite their prevalence, the underpinning mechanismsand pathobiology remain elusive, limiting treatment options. Herein, we review emerging causes, molecular and functional processes, and mechanisms at play, and discuss research and clinical gaps. We consider the iatrogenic and psychogenic effects of chemotherapy and highlight the need to distinguish chemotherapy-related headaches from primary headache disorders in cancer patients, including migraines or tension-type headaches. We discuss evolving biomarkers and mechanistic models that could facilitate the differential diagnosis and development of effective interventions. Given the global rise of cancer burden and better outcomes of chemotherapy with longer life expectancy, recognition of the detrimental impact of chemotherapy-related headaches and their integration into management plans are expected to improve treatment adherence and post-treatment life quality.  \nKeywords: chemotherapy-related headaches; neuroinflammation; blood-brain barrier disruption; systemic toxicity; pain management  \n1. Introduction  \nChemotherapy encompasses a diverse range of pharmacological treatments designed to selectively target and eliminate rapidly dividing cancer cells through various mechanisms, including DNA alkylation, topoisomerase inhibition, antimetabolite activity, and microtubule disruption. While this approach has significantly improved survival rates and  \ndisease management, it is not without complications. The limited selectivity of chemotherapy results in harmful effects that extend beyond cancerous cells, influencing the functions of various organs and systems","cbCaitQdqZ4vfcan","https://ap.wps.com/l/cbCaitQdqZ4vfcan","pdf",2356468,35,"English","# Abstract\n# Introduction\n## Chemotherapy complications and neurological vulnerability\n## Chemotherapy-related headaches as a distinct clinical entity\n# Table 1: Comparative incidence and co-occurrence with CRHs","[{\"question\":\"Why are chemotherapy-related headaches a major problem for cancer patients?\",\"answer\":\"They significantly affect well-being and treatment adherence, contributing to reduced compliance and deterioration of patient quality of life.\"},{\"question\":\"What does the review claim about the pathobiology of chemotherapy-related headaches?\",\"answer\":\"Although such headaches are prevalent, the mechanisms and pathobiology are described as elusive, and mechanistic and translational studies remain scarce.\"},{\"question\":\"How should chemotherapy-related headaches be differentiated from other headache disorders?\",\"answer\":\"The review highlights the need to distinguish chemotherapy-related headaches from primary headache disorders in cancer patients, including migraines and tension-type headaches.\"}]","Redefining Chemotherapy-Related Headaches - From Pathobiology to Differential Diagnosis and Management | PDF",1790769941,88]